Long-Acting PrEP Could Be Here As Early As 2022
HOLLYWOOD LGBTQ COUNCIL
Last Thursday, as industry publication Fierce Pharma reported, the U.S. Food and Drug Administration granted priority review status to cabotegravir, a long-acting version of pre-exposure prophylaxis (PrEP) made by the pharmaceutical company ViiV Healthcare, which is majority-owned by GlaxoSmithKline. The drug will now undergo a shortened six-month review period rather than the standard 10-month period. The FDA could issue its decision on the drug, commercially known as Cabenuva, as early as January of next year, as Fierce Pharma noted. If cabotegravir passes priority review, it would become the first available medication of its kind.